Skip to main content
main-content

Rheumatoid arthritis

Feature content

07-06-2019 | Rheumatoid arthritis | Case study | Article

Tofacitinib in a patient with refractory severe rheumatoid arthritis

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase III trials

medwireNews summarizes the completed and ongoing phase III trials of JAK inhibitors in patients with rheumatoid arthritis.

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

19-12-2018 | Diagnosis and screening | Podcast | Video

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

07-09-2018 | Treatment | Feature | Article

At a glance: Common scores used in rheumatology

A quick-reference guide to the scores that are commonly used in clinical trials and daily rheumatology practice.

09-02-2018 | Rheumatoid arthritis | Feature | News

Should treatment be tapered in patients with RA?

medwireNews speaks to Vivian Bykerk about whether treatment should be tapered in patients with rheumatoid arthritis.

19-12-2017 | Medications | Editorial | Article

Managing antirheumatic medication in patients undergoing elective arthroplasty

Editorial Board member Oliver FitzGerald reviews the recent guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.

24-10-2017 | Rheumatoid arthritis | Editorial | Article

Demise of the triple

Editorial Board member Marc Cohen reviews the use of triple therapy for the treatment of rheumatoid arthritis, and discusses the possible reasons for its underutilization compared with biologic therapies.

12-09-2017 | Rheumatoid arthritis | Feature | Article

At a glance: Trials evaluating baricitinib in RA

Our quick guide to the phase II and III trials of baricitinib for the treatment of rheumatoid arthritis. 

16-08-2017 | Depression | Practical approach | Article

Identification and treatment optimization of comorbid depression in rheumatoid arthritis

A practical approach focusing on outlining recommendations for identifying and treating comorbid depression among rheumatoid arthritis patients, to be implemented within a rheumatology clinic setting.​​​​​​​

Mellissa H. Withers MH, Gonzalez LT, Karpouzas GA. Rheumatol Ther 2017. doi:10.1007/s40744-017-0072-4

14-08-2017 | Respiratory disorders | Practical approach | Article

Practical management of respiratory comorbidities in patients with rheumatoid arthritis

The authors summarize the international recommendations for the management of respiratory comorbidities in rheumatoid arthritis and propose practical management suggestions to aid informed decision-making.

Bluett J, Jani M, Symmons DPM. Rheumatol Ther 2017. doi:10.1007/s40744-017-0071-5

04-08-2017 | Rheumatoid arthritis | Feature | Article

At a glance: The ORAL trials of tofacitinib for the treatment of RA

Our quick-reference guide to the seven ORAL trials of tofacitinib for the treatment of rheumatoid arthritis that have been completed to date.

27-07-2017 | Cardiovascular disease | Practical approach | Article

Practical management of cardiovascular comorbidities in rheumatoid arthritis

The authors provide a practical update on the main aspects of prevention and treatment of cardiovascular comorbidities in rheumatoid arthritis, focusing on atherosclerotic cardiovascular disease. ​​​​​​

Gualtierotti R, Ughi N, Marfia G, Ingegnoli F. Rheumatol Ther 2017. doi:10.1007/s40744-017-0068-0

19-07-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors for RA: Professor Roy Fleischmann speaks to medwireNews

Roy Fleischmann talks to medwireNews about the need for JAK inhibitors and their potential impact on the rheumatoid arthritis treatment landscape.

05-06-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis?

medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.

15-05-2017 | Malignancy | Practical approach | Article

Malignancy incidence, management, and prevention in patients with rheumatoid arthritis

Wilton and Matteson discuss malignancy in patients with rheumatoid arthritis, observing that it is a major comorbidity related to both the disease and its treatment.

Wilton KM, Matteson EL. Rheumatol Ther 2017. doi:10.1007/s40744-017-0064-4

Image Credits